Abbvie Inc Stock Price, News & Analysis

AbCellera (ABCL) has expanded its collaboration with AbbVie (ABBV) to develop novel T-cell engagers (TCE) in oncology, building upon their partnership from December 2022. The expanded agreement gives AbbVie access to AbCellera's TCE platform for developing therapeutic antibodies targeting tumors.

Under the agreement terms, AbCellera will lead discovery activities while AbbVie retains development and commercialization rights for resulting therapeutic antibodies. AbCellera will receive upfront and research payments, plus potential downstream milestone payments and tiered royalties on net sales.

AbbVie (NYSE: ABBV) and Simcere Zaiming have announced a partnership to develop SIM0500, a novel trispecific antibody for multiple myeloma. The drug candidate, currently in Phase 1 clinical trials in China and the U.S., targets GPRC5D, BCMA, and CD3 using Simcere's T-cell engager polyspecific antibody technology platform.

The agreement includes an upfront payment from AbbVie to Simcere Zaiming, with potential option fees and milestone payments reaching up to $1.055 billion, plus tiered royalties on net sales outside Greater China. AbbVie will receive tiered royalties on sales within the Greater China territory. SIM0500 has demonstrated strong T cell cytotoxicity against multiple myeloma cells through various antitumor effects.

AbbVie (ABBV) and REGENXBIO (RGNX) have announced key updates for their ABBV-RGX-314 clinical program. The companies expect pivotal data on the safety and efficacy of subretinal delivery for wet age-related macular degeneration (wet AMD) patients in 2026 through the ATMOSPHERE® and ASCENT™ trials.

Additionally, both companies will plan a Phase 3 clinical program for diabetic retinopathy (DR) treatment using suprachoroidal delivery via the SCS Microinjector®. This gene therapy aims to address the treatment burden of chronic, frequent dosing in retinal diseases, which are among the leading causes of blindness. ABBV-RGX-314 is being developed as the first potential one-time gene therapy for both wet AMD and DR patients.

AbbVie (ABBV) has announced its upcoming participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's management will engage in a fireside chat on Wednesday, January 15, 2025, at 10:15 a.m. Central time.

Investors and interested parties can access a live audio webcast of the presentation through AbbVie's Investor Relations website at investors.abbvie.com. For those unable to attend the live session, an archived version will be made available later the same day.

Allergan Aesthetics, an AbbVie company (NYSE: ABBV), has launched its third annual CoolMonth campaign featuring CoolSculpting® Elite, the leading non-surgical fat reduction treatment. The promotion includes two key offers: a $300 discount for first-time patients valid through February 6, 2025, and a sweepstakes opportunity to win $10,000 for patients who get treated by March 24, 2025.

To participate, customers must join Allē, Allergan Aesthetics' free loyalty program. CoolSculpting® Elite is FDA-cleared for treating visible fat bulges in various body areas, including thigh, abdomen, flank, bra fat, back fat, under buttocks, and upper arm for patients with specific BMI requirements.

AbbVie (NYSE: ABBV) has announced it will release its full-year and fourth-quarter 2024 financial results on Friday, January 31, 2025, before market opening. The company will host a live webcast earnings conference call at 8 a.m. Central time, which will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived version of the session will be made available later that day.

AbbVie (NYSE: ABBV) has announced a definitive agreement to acquire Nimble Therapeutics for $200 million in cash, with additional potential milestone-based payments. The acquisition includes Nimble's lead asset, an investigational oral peptide IL23R inhibitor in preclinical development for psoriasis and inflammatory bowel disease (IBD), along with other novel oral peptide candidates for autoimmune diseases.

The deal also encompasses Nimble's proprietary peptide synthesis, screening, and optimization platform, which accelerates the discovery and optimization of peptide candidates. The IL23R inhibitor targets a clinically validated therapeutic pathway in autoimmune diseases, particularly affecting psoriasis and IBD pathogenesis through increased inflammation and amplified immune responses.

AbbVie (ABBV) has completed its acquisition of Aliada Therapeutics, strengthening its neuroscience pipeline with ALIA-1758, a potential best-in-class disease-modifying therapy for Alzheimer's disease currently in Phase 1 clinical trials. The acquisition brings two key assets: the anti-pyroglutamate amyloid beta antibody ALIA-1758, and a novel blood-brain barrier (BBB)-crossing technology that enhances delivery of targeted drugs into the central nervous system. This strategic move positions AbbVie to address the growing challenge of Alzheimer's disease, which affects millions globally and is becoming more prevalent with aging populations.

AbbVie (ABBV) announced new results from two ongoing clinical trials of epcoritamab in patients with diffuse large B-cell lymphoma (DLBCL). The Phase 1b/2 EPCORE NHL-2 trial showed 100% overall response rate and 87% complete response rate in untreated high-risk DLBCL patients when combined with R-CHOP therapy. Among complete responders, 83% remained in remission after two years.

The Phase 2 EPCORE NHL-1 trial's three-year follow-up, evaluating epcoritamab monotherapy in relapsed/refractory patients, demonstrated 59% overall response rate and 41% complete response rate. Among complete responders, 52% maintained response at three years, with median complete response duration of 36.1 months.